Patent ID: 11860163
Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
Field: Pharmaceuticals (Chemistry)
Classification: CPC G  A  C | IPC A  G

Claim 3:
4. A method for treating a subject having a cancer, comprising:
(a) administering a CAR T cell therapy to the subject,
(i) wherein the subject is identified as likely to have a response to a CAR T cell therapy, and the level of a bacterium or spores thereof in a sample of the subject is lower than a reference bacterium or spores thereof level, wherein the bacterium is selected from the group consisting of bacteria of the Peptostreptococcaceae family, bacteria of the Bacteroidaceae family, bacteria of the Clostridiaceae family, and any combinations thereof; and/or
(ii) wherein the subject is identified as likely to have a response to a CAR T cell therapy, and the level of a bacterium or spores thereof in a sample of the subject is higher than a reference bacterium or spores thereof level, wherein the bacterium is selected from the group consisting of bacteria of the Lachnospiraceae family, bacteria of the Rikenellaceae family, bacteria of the Lactobacillaceae family, bacteria of the Oscillospiraceae family, bacteria of the Ruminococcaceae family, bacteria of the Acidaminococcaceae family, bacteria of the Clostridiaceae family, bacteria of the Peptococcaceae family and any combinations thereof; and/or
(iii) wherein the subject is identified as likely to have a response to a CAR T cell therapy, and the level of a bacterial gene in a sample of the subject is lower than a reference bacterial gene level, wherein the bacterial gene is selected from the group consisting of genes involved in vitamin B biosynthesis or secondary bile acid biosynthesis or degradation; or

(b) administering a therapeutic bacterium or spores thereof or a pharmaceutical composition comprising thereof to the subject,
(i) wherein the subject is identified as likely to have no response or a poor response to a CAR T cell therapy, and the level of a bacterium or spores thereof in a sample of the subject is higher than a reference bacterium or spores thereof level, wherein the bacterium is selected from the group consisting of bacteria of the Peptostreptococcaceae family, bacteria of the Bacteroidaceae family, bacteria of the Clostridiaceae family, and any combinations thereof;
(ii) wherein the subject is identified as likely to have no response or a poor response to a CAR T cell therapy, and the level of a bacterium or spores thereof in a sample of the subject is lower than a reference bacterium or spores thereof level, wherein the bacterium is selected from the group consisting of bacteria of the Lachnospiraceae family, bacteria of the Rikenellaceae family, bacteria of the Lactobacillaceae family, bacteria of the Oscillospiraceae family, bacteria of the Ruminococcaceae family, bacteria of the Acidaminococcaceae family, bacteria of the Clostridiaceae family, bacteria of the Peptococcaceae family and any combinations thereof; and/or
(iii) wherein the subject is identified as likely to have no response or a poor response to a CART cell therapy, and the level of a bacterial gene in a sample of the subject is higher than a reference bacterial gene level, wherein the bacterial gene is selected from the group consisting of genes involved in vitamin B biosynthesis or secondary bile acid biosynthesis or degradation,

wherein the reference bacterium or spores thereof level is a level of the bacterium or spores thereof in a patient that had a CAR T cell therapy response and/or the reference bacterial gene level is a level of the bacterial gene in a patient that had a CAR T cell therapy response.